Percheron Therapeutics Crescita futura

Future criteri di controllo 5/6

Percheron Therapeutics prevede che gli utili e i ricavi cresceranno rispettivamente di 19.8% e 45.3% all'anno. Si prevede che l'EPS crescerà di 29% all'anno. Si prevede che il ritorno sul capitale proprio sarà di -231.6% in 3 anni.

Informazioni chiave

19.8%

Tasso di crescita degli utili

29.0%

Tasso di crescita dell'EPS

Pharmaceuticals crescita degli utili	23.9%
Tasso di crescita dei ricavi	45.3%
Rendimento futuro del capitale proprio	-231.6%
Copertura analitica	Low
Ultimo aggiornamento	07 Nov 2024

Aggiornamenti recenti sulla crescita futura

Nessun aggiornamento

Recent updates

Previsioni di crescita degli utili e dei ricavi

OTCPK:PERC.F - Stime future degli analisti e dati finanziari passati (AUD Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
6/30/2027	11	6	-38	-38	2
6/30/2026	1	-20	-16	-16	3
6/30/2025	1	-40	-17	-17	2
6/30/2024	3	-12	-10	-10	N/A
3/31/2024	3	-11	-10	-10	N/A
12/31/2023	2	-11	-10	-10	N/A
9/30/2023	2	-11	-9	-9	N/A
6/30/2023	2	-11	-8	-8	N/A
3/31/2023	2	-10	-7	-7	N/A
12/31/2022	2	-8	-7	-7	N/A
9/30/2022	2	-7	-7	-7	N/A
6/30/2022	2	-6	-8	-8	N/A
3/31/2022	1	-7	-8	-8	N/A
12/31/2021	1	-9	-8	-8	N/A
9/30/2021	1	-9	-7	-7	N/A
6/30/2021	1	-8	-6	-6	N/A
3/31/2021	1	-6	-5	-5	N/A
12/31/2020	1	-4	-4	-4	N/A
9/30/2020	1	-5	-4	-4	N/A
6/30/2020	1	-6	-4	-4	N/A
3/31/2020	1	-6	-3	-3	N/A
12/31/2019	1	-6	-3	-3	N/A
9/30/2019	1	-4	-3	-3	N/A
6/30/2019	1	-3	-3	-3	N/A
3/31/2019	0	-3	-3	-3	N/A
12/31/2018	0	-3	-3	-3	N/A
9/30/2018	0	-3	-3	-3	N/A
6/30/2018	0	-2	-2	-2	N/A
3/31/2018	0	-2	N/A	-2	N/A
12/31/2017	0	-2	N/A	-3	N/A
9/30/2017	1	-3	N/A	-3	N/A
6/30/2017	1	-3	N/A	-3	N/A
3/31/2017	1	-2	N/A	-2	N/A
12/31/2016	1	-2	N/A	-2	N/A
9/30/2016	2	-2	N/A	-2	N/A
6/30/2016	2	-3	N/A	-2	N/A
3/31/2016	3	-1	N/A	-1	N/A
12/31/2015	4	1	N/A	0	N/A
9/30/2015	5	1	N/A	1	N/A
6/30/2015	5	1	N/A	1	N/A
3/31/2015	3	-1	N/A	-1	N/A
12/31/2014	1	-3	N/A	-3	N/A
9/30/2014	1	-3	N/A	-3	N/A
6/30/2014	1	-3	N/A	-3	N/A
3/31/2014	1	-3	N/A	-2	N/A
12/31/2013	1	-3	N/A	-2	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che PERC.F diventerà redditizio nei prossimi 3 anni, il che è considerato una crescita più rapida del tasso di risparmio ( 2.6% ).

Guadagni vs Mercato: Si prevede che PERC.F diventerà redditizia nei prossimi 3 anni, il che è considerato una crescita superiore alla media del mercato.

Guadagni ad alta crescita: Si prevede PERC.F diventerà redditizia nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di PERC.F ( 45.3% all'anno) crescerà più rapidamente del mercato US ( 8.9% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di PERC.F ( 45.3% all'anno) crescerà più rapidamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che PERC.F non sarà più redditizia tra 3 anni.

Percheron Therapeutics Crescita futura

Future criteri di controllo 5/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Recent updates

Percheron Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 13.01854 million.

Percheron Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 0.185287 million.

Percheron Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 2 million.

Percheron Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 13.01854 million.

Antisense Therapeutics Limited, Annual General Meeting, Nov 15, 2023

Antisense Therapeutics Limited Receives MHRA Approval for ATL1102 Phase IIb DMD Clinical Trial in UK

Antisense Therapeutics Limited Announces the Appointment of James Garner as Chief Executive Officer, Effective 07 August 2023

Antisense Therapeutics Limited Receives Regulatory Authority Approval from the Turkish Medicines and Medical Device Agency

Antisense Therapeutics Limited Commences the Second Phase (Chronic Setting) of Its Program to Study the Effects of an Antisense Oligonucleotide (ASO) to CD49d (Mouse Equivalent of ATL1102) in a LGMDR2 Animal Model of Dysferlin Deficiency

Antisense Therapeutics Limited Reports Initial Positive Muscle Functional Data from A DMD

Antisense Therapeutics Limited Announces Clinical Trial Application Submit for ATL1102 Phase IIb DMD trial conduct in Europe

Antisense Therapeutics Limited Announces Retirement of Mark Diamond as Chief Executive Officer

Antisense Therapeutics Limited Initiates the Process with Contract Research Organisation Pharmaron

Antisense Therapeutics Limited, Annual General Meeting, Nov 17, 2022

Antisense Therapeutics Limited Announces Appointment of Anthony Filippis as Chief Commercial Officer

Antisense Therapeutics Limited Announces Dosing Commenced in DMD Combination Therapy Study

Antisense Therapeutics Limited Intends to Conduct Double-Blind, Placebo Controlled Six Month Dosing Trial of Atl1102 Followed by Six Month Open Label Phase

Antisense Therapeutics Limited Announces Long COVID-19 Study Identifies Novel Blood Markers as Potential Diagnostic and Therapeutic Targets

Antisense Therapeutics Limited Announces Outcomes from Its Collaboration to Study the Neurological Aspects of Long COVID-19

Antisense Therapeutics Limited Announces ATL1102 DMD Clinical Trial Application Submitted in Europe

Antisense Therapeutics Limited Announces Results from First Study of Antisense to CD49d in Limb Girdle Muscular Dystrophy R2 Mouse Model

Antisense Therapeutics Limited Announces the Results from A First Study of Antisense to CD49d in A Limb Girdle Muscular Dystrophy R2 (LGMDR2) Mouse Model

Antisense Therapeutics Limited Announces Dosing Commenced in MCRI Collaboration Animal Study

Antisense Therapeutics Limited Announces New Data Supports ATL1102s Broader Clinical Potential

Antisense Therapeutics Limited Announces US FDA Feedback on Type C Meeting for ATL1102 in the US

Antisense Therapeutics Limited Announces Manufacture of ATL1102 clinical supplies for Phase IIb trial

Antisense Therapeutics Limited Announces the Paediatric Investigation Plan for ATL1102 in DMD Submitted to European Medicines Agency

Antisense Therapeutics Limited Announces Executive Changes

Antisense Therapeutics Limited, Annual General Meeting, Dec 18, 2020

Antisense Therapeutics Limited Announces Statistically Significant Improvement in Pul2.0 with Atl1102 Treatment in Non-Ambulant Boys with DMD Compared to A Matched Natural History Control

An unknown buyer acquired a 49% stake in Antisense Therapeutics Limited (ASX:ANP) from Opthea Limited (ASX:OPT) for AUD 0.34 million.

Antisense Therapeutics Limited Auditor Raises 'Going Concern' Doubt

Previsioni di crescita degli utili e dei ricavi

Previsioni di crescita futura degli analisti

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

Scoprire le aziende in crescita